Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/550274


European Head and Neck Cancer Therapeutics Markets


Description: This Frost & Sullivan research service titled European Head and Neck Cancer Therapeutics Markets provides market drivers, restraints and revenue forecasts for this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the chemotherapy and targeted therapies markets.

Targeted Therapy Improves Survival Rates among Patients with Head and Neck Cancer

Physicians in Europe are eager for novel therapies for head and neck cancer, as five-year survival rates among patients have remained low at 33.0 per cent for decades. Some of the new drugs that fall under targeted therapies have eliminated the shortcomings of traditional chemotherapy treatment by predominantly acting only on the cancer cells and leaving the healthy cells intact. These drugs achieve this precision by interfering with specific molecules involved in carcinogenesis and tumour growth. "An example of targeted therapy is Erbitux (cetuximab), a first in class IgG1 monoclonal antibody (mAb), specifically targeting the epidermal growth factor receptor (EGFR)," says the analyst of this research service. "mAbs are highly specific therapeutics and have improved side effects profiles."

Most targeted therapies in the head and neck cancer segment are in clinical trials, as developers are hoping to test the viability of these therapies as stand-alone drugs as well as in combination with other therapies such as chemotherapy. Targeted therapy has scored over current treatments and is proving effective against a range of cancers including breast, colon, lung, kidney, head and neck and lymphoma.

Awareness Campaigns Required to Disseminate Information about Therapies for the Rarely-occurring Head and Neck Cancers

People have too little knowledge about head and neck cancers, as these are not as prevalent as other cancers. This insufficient information leads to delayed diagnosis and thus, late stage treatment, which greatly hampers pharmaceutical companies’ market growth. While later diagnosis could dramatically reduce the survival rate, earlier diagnosis could possibly mean a five-year survival rate of 70.0 to 90.0 per cent. Market participants need to target education and medical awareness programmes at the public and healthcare professionals, which work within multi-disciplinary teams, to promote early diagnosis.

Pharmaceutical companies also need to convince the public about the advantages of these prohibitively expensive products if they are to experience higher uptake. "Until the benefits of the drugs have been clearly demonstrated in terms of overall cost savings and effectiveness, the use of this form of therapy is likely to remain restricted to very specific and wealthy patient populations," notes the analyst. "Biopharmaceutical and pharmaceutical companies should assess themselves and provide detailed and clear pharmacoeconomic analysis of these products so that mAbs become less restricted and reimbursement may be granted to additional patient groups."


Contents: 1. Executive Summary
-1. Overview
--1. Overview of the Head and Neck Cancer Therapeutics Market

2. Glossary of Terms
-1. List of Terms
--1. Abbreviations

3. Market Overview
-1. Introduction
--1. Disease Characteristics
--2. Epidemiology
-2. Market Definition and Segmentation
--1. Definition
--2. Segmentation

4. Research Methodology
-1. Research Objectives and Scope
--1. Methodology
--2. Assumptions and Limitations

5. Industry Challenges
-1. Industry Challenges for the European Head and Neck Cancer Therapeutics Markets
--1. Challenges Faced by Pharmaceutical Companies

6. Total European Head and Neck Cancer Therapeutics Market
-1. Overview and Definitions
--1. Introduction
--2. Market Drivers
---a. Unmet needs offer scope for new treatment options
---b. Targeted therapy broadens treatment opportunities
---c. Combination therapies setting new standards of care for adjuvant therapy
---d. Earlier diagnosis due to increasing awareness
---e. Higher incidence of head and neck cancer increasing market potential
--3. Market Restraints
---a. High cost of targeted therapies limit uptake
---b. Lower incidence rates compared to other diseases limits R&D expenditure
---c. Fewer medicines in development for cancer than other diseases
---d. Patent expiries of generics increase pressure on pharma companies
--4. Current Therapeutic Options
--5. Future Therapeutic Approaches
--6. Current Treatment Guidelines
--7. Pricing Trends
--8. Market Engineering Measurement Analysis
-2. Competitive Analysis
--1. Profiles of Key Industry Participants and Market Share Analysis
--2. Pipeline Analysis

7. Total Forecasts for the European Head and Neck Cancer Therapeutics Market
-1. Forecasts
--1. Patient Forecasts
--2. Market Revenue Forecasts
--3. Geographical Trends
--4. Forecasts of Recent Entrants - Erbitux

8. Pricing and Reimbursements
-1. Pricing and Reimbursement Issues
--1. Pricing and Reimbursement

9. Strategic Recommendations for the European Head & Neck Cancer Therapeutics Market
-1. Market Engineering Recommendations
--1. Strategic Recommendations

10. Database of Key Industry Participants
-1. Key Industry Participants
--1. Key Participants in the Head and Neck Cancer Therapeutics Market

11. Decision Support Databases
-1. Habitual Indicators
--1. Prevalence of Smokers
--2. Prevalence of Male Smokers
--3. Prevalence of Female Smokers
--4. Alcohol Consumption
-2. Healthcare Expenditure
--1. Expenditure
--2. Pharmaceutical R&D Expenditure
-3. Demography
--1. Female Population Aged 65 Years and Above
--2. Male Population Aged 65 Years and Above
--3. Population Aged 65 Years and Above
--4. Percent of Population Aged 65 Years and Above




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/550274

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 29/11/2009 22:29:37
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
European Head and Neck Cancer Therapeutics Markets
Web Address:
http://www.researchandmarkets.com/reports/550274
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Site License €4,365.00
Electronic (PDF) - Enterprisewide €5,373.00
Electronic and Hard Copy (PDF) - Enterprisewide €5,709.00 + EUR€ 50.00 Shipping/Handling *
Electronic and Hard Copy (PDF) - Site License €4,701.00 + EUR€ 50.00 Shipping/Handling *
* Shipping/Handling is only charged once per order.


Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 29/11/2009 22:29:37

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)